Wuhan Institute of Virology

What Wuhan Institute of Virology does

The Wuhan Institute of Virology (WIV) is a state-owned research institute established in 1956 under the Chinese Academy of Sciences, specializing in basic virology research, pathogen identification, antiviral drug screening, vaccine development, and biosafety science. Originally founded as the CAS Wuhan Microbiology Laboratory and renamed in 1978 to reflect its virology focus, the institute today operates four research centers covering new and emerging infectious diseases, molecular virology and pathology, analytical microbiology and nanobiology, and microbial resources and bioinformatics. It maintains China's only operational biosafety level 4 (P4) laboratory — operational since 2018 — as well as the National Virus Resource Bank, which functions as the country's primary repository for standardized virus strains. Its customers are predominantly Chinese central and provincial government bodies, public hospitals, and academic partners; the institute is funded through government grants and contracts rather than commercial sales.

WIV's core technology stack centers on pathogen identification, virus isolation and culture, antiviral drug screening, vaccine development, and biosafety testing. Documented capabilities include the first-in-the-world determination of the SARS-CoV-2 genome sequence (January 2, 2020), virus strain isolation (January 5, 2020), global sharing of the genome via GISAID (January 11, 2020), screening of 1,609 compounds yielding 70 candidate antivirals (including Remdesivir and Chloroquine), and development of the world's first inactivated COVID-19 vaccine to enter clinical trials on April 12, 2020. Supporting platforms include the National Key Laboratory for High-Pathogenic Viruses and Biosafety, the China Virus Resource Basic Database, the China Epidemic Viral Pathogen Investigation Database, a scientific digital library, a virus museum, and the Zhengdian high-containment campus that came fully online in 2023.

WIV does not operate a commercial business model. Funding flows from the Chinese Academy of Sciences, the Ministry of Science and Technology, the National Natural Science Foundation of China, and provincial departments of science and technology through multi-year research contracts, project grants, and emergency scientific research allocations. Services are delivered via research collaboration, joint laboratories, technology transfer, and government contracts. Distribution of research outputs occurs through peer-reviewed publications, the National Virus Resource Bank sharing platform, and the GISAID global virus sequence database. The institute's primary external counterparties include the National Health Commission, the Hubei Provincial Department of Science and Technology, multiple provincial CDCs, the Academy of Military Medical Sciences, the Chinese Academy of Medical Sciences, and Wuhan Jinyintan Hospital.

Name

Wuhan Institute of Virology

Legal name

中国科学院武汉病毒研究所

Website

https://whiov.cas.cn

Company type

Private

Founded year

1956

Operating status

Operating

Headcount range

1–10 employees

Short description

Wuhan Institute of Virology is a Chinese Academy of Sciences research institute that performs basic virology research, operates China's only operational BSL-4 laboratory and National Virus Resource Bank, and serves national biosecurity, public health authorities, and academic collaborators.

Ownership category

akta.pro rank

Product category

Virology Research and Biosafety Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Biological Product (except Diagnostic) Manufacturing (325414), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Biological Products, (No Disgnostic Substances) (2836)

akta.pro industry

PRIMARYHLAGAEAF

Microbiology & Infectious Disease Testing (Trial Support)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

SECONDARYHLAAAEAC

Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens)

Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

SECONDARYHLAJAIAN

Laboratory Informatics & Reporting (LIMS/ELR) Public Health Networks

Healthcare & Life Sciences/Public Health, Government & Regulators/Public Health Laboratories & Reference Testing Networks

SECONDARYHLAAALAC

Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels)

Healthcare & Life Sciences/Biotechnology & Biologics/Diagnostics (Biotech-related)

Keywords

• Virology research
• Biosafety laboratory
• Infectious disease research
• Antiviral drug screening
• Vaccine development

Headquarters

HQ city

Wuhan

HQ country

China

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Technology or R&D, Operations, Supply Chain, Others

Revenue model

1. Government Research Funding: Primary funding from Chinese Academy of Sciences, Ministry of Science and Technology, National Natural Science Foundation of China, and other government bodies for basic research, applied research, and strategic technology development

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

Wuhan Institute of Virology is a government research institution under the Chinese Academy of Sciences that conducts basic virology research, pathogen identification, antiviral drug screening, vaccine development, and operates China's only Biosafety Level 4 (P4) laboratory. Its offerings include the National Virus Resource Bank for virus preservation and distribution, the Wuhan National Biosafety Laboratory for high-containment research, the National Key Laboratory for High-Pathogenic Viruses and Biosafety, and specialized scientific databases supporting domestic and international virology research.

Product overview

Wuhan Institute of Virology operates as a research institution under the Chinese Academy of Sciences, providing scientific database services and research platforms rather than commercial products. The institute's core offerings include the National Virus Resource Bank for virus preservation and sharing, the Wuhan National Biosafety Laboratory (P4) for high-containment research, the National Key Laboratory for High-Pathogenic Viruses and Biosafety, and specialized scientific databases including the China Virus Resource Basic Database and China Epidemic Viral Pathogen Investigation Database. Supporting platforms include a Scientific Digital Library and Professional Search services for virology research.

Differentiator

Problem solved

Functional benefit

Products and services

• National Virus Resource Bank (国家病毒资源库) National-level virus resource preservation and sharing platform serving as China's only professional institution for virus resource collection, preservation, and distribution. Provides standardized virus strains and genetic resources to qualified research institutions nationwide, supporting national biosafety, life science research, and population health.
• Scientific Digital Library (科学数字图书馆) Digital library service providing access to scientific literature and research resources for virology and related fields, supporting researchers in accessing institutional and external research publications.
• Professional Search (专业检索) Professional search service for virus-related research literature and scientific databases, providing researchers with targeted access to virology publications and resources.
• China Virus Resource Basic Database (中国病毒资源基础数据库) Foundational database containing fundamental virus resource data supporting virology research and pathogen investigation, providing standardized virus information for research use.
• China Epidemic Viral Pathogen Investigation Database (中国流行病毒性病原调查数据库) Database platform for investigating and documenting epidemic viral pathogens circulating in China, supporting epidemiological surveillance and outbreak investigation research.
• Pathogen Identification Services Rapid pathogen identification and origin tracing services for government health authorities and hospitals, demonstrated through the institute's first-in-the-world identification of the SARS-CoV-2 genome sequence in January 2020 from clinical samples.
• Antiviral Drug Screening Services Compound screening and antiviral drug evaluation services supporting vaccine and therapeutic development, including the COVID-19 effort that screened 1,609 compounds and identified 70 candidate antivirals including Remdesivir and Chloroquine.

Quantifiable outcome

• First to identify SARS-CoV-2 genome sequence globally within 72 hours of receiving samples (Jan 2, 2020)
• +4 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

15 partnerships are on record, tiered major and core.

• Zhongnan Hospital of Wuhan University (武汉大学中南医院)majorStrategic or Co-development Partner · 20 January 2024Medical Innovation Joint Research Center established for academic exchange and collaborative research between institute and hospital.
• Chinese Academy of Medical Sciences, Pathogenic Biology Institute (中国医学科学院病原生物学研究所)majorStrategic or Co-development Partner · 1 June 2023Research exchange visit covering history, development planning, talent team building, platform and resource bank construction, major research tasks and achievements.
• Institute of Medical Biologyology, Chinese Academy of Medical Sciences (中国医学科学院医学生物学研究所)majorStrategic or Co-development Partner · 1 June 2023Visited high-containment biosafety laboratories, discussed medical science research, especially full-chain vaccine research and production capabilities.
• Kunming Institute of Zoology, CAS (中国科学院昆明动物研究所)majorStrategic or Co-development Partner · 1 June 2023Visited national major science facility for primate phenotype and genetics research and national Kunming high-containment primate animal experiment center. Discussed 'Fourteenth Five-Year' planning, national key laboratory restructuring, and organizational research models.
• Wuhan University (武汉大学)coreStrategic or Co-development Partner · 11 May 2023Joint national key laboratory collaboration with Wuhan University for shared academic exchange and research cooperation.
• Shanghai Institute of Materia Medica, CAS (中国科学院上海药物研究所)majorStrategic or Co-development Partner · 28 April 2023Academic exchange meeting on COVID-19 collaborative drug research held to share experiences and explore further cooperation in antiviral drug development.
• Zhuhai Livzon Reagent Inc. (珠海丽珠试剂股份有限公司)majorStrategic or Co-development Partner · 1 February 2020Collaboration on development of COVID-19 IgG/IgM serological diagnostic kit using enzyme-linked immunosorbent assay method. Institute provided recombinant viral antigens, partner developed and manufactured diagnostic products.
• Jinyintan Hospital, Wuhan (金银潭医院)coreStrategic or Co-development Partner · 23 January 2020Joint laboratory established for COVID-19 research collaboration. Institute provided pathogen identification, virus isolation, and testing support while hospital provided clinical samples and patient coordination. Major discoveries including first virus isolation were achieved through this partnership.
• Hubei Province Emergency Scientific Research Consortium (湖北省新型肺炎应急科研攻关专家组)coreStrategic or Co-development Partner · 23 January 202013-institution consortium led by Wuhan Institute of Virology with researchers from Huazhong Agricultural University, Huazhong University of Science and Technology, Wuhan University, Hubei Provincial Hospital of Chinese Medicine, and Wuhan Jinyintan Hospital. Focused on rapid detection technology, disease mechanisms, and therapeutic drug development.
• National Emergency Prevention and Control Drug Engineering Technology Research Center, Academy of Military Medical Sciences (军事科学院军事医学研究院国家应急防控药物工程技术研究中心)coreStrategic or Co-development Partner · 1 January 2020Joint research on antiviral drug screening resulting in identification of Remdesivir and Chloroquine as effective inhibitors of SARS-CoV-2 in cell-based assays. Collaborative paper published in Cell Research.
• Shanghai Sailunno Biotechnology Co., Ltd. (上海赛伦生物技术股份有限公司)majorStrategic or Co-development Partner · 1 January 2020Collaboration on development of anti-novel coronavirus immune globulin F(ab')2 product. Shanghai Sailunno provided horse breeding facilities and plasma collection while institute provided research design and immunological expertise. Product reached new drug application stage by March 2020.
• Wuhan Yizhiyou Biopharmaceutical Co., Ltd. (武汉友芝友生物制药有限公司)majorStrategic or Co-development Partner · 1 January 2020Provided mammalian cell high-density fermentation technology for recombinant protein expression in support of COVID-19 vaccine and therapeutic antibody research.
• French Institutions (France-China New Infectious Disease Cooperation)majorStrategic or Co-development Partner · 1 October 2012Long-standing China-France cooperation in new infectious disease prevention and control. Second China-France New Infectious Disease Seminar held in 2012 with French Ambassador and Health Minister attendance.
• Shenzhen Center for Disease Control and Prevention (深圳市疾病预防控制中心)majorStrategic or Co-development Partner · 1 June 2012Joint establishment of 'Southern Virus Disease Research Center' for collaborative virus disease research in southern China.
• Jiangxia District People's Government, Wuhan (武汉市江夏区人民政府)majorStrategic or Co-development Partner · 1 June 2012Comprehensive cooperation framework agreement signed for district-institute collaboration in science and technology development.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Institut Pasteur: France's premier virology and infectious disease research institute with a global network and BSL-4 capability; directly comparable to WIV as a national virology reference center with pathogen identification, vaccine research, and international collaboration mandates.
• Bernhard Nocht Institute for Tropical Medicine: Germany's reference center for tropical and emerging infectious diseases with BSL-4 laboratory capacity; directly comparable to WIV in pathogen identification, virology research, and serving as a national biosecurity asset.
• Beijing Institute of Microbiology and Epidemiology: Chinese military-affiliated institute under the Academy of Military Medical Sciences that conducts high-containment pathogen research and collaborated with WIV on Remdesivir/Chloroquine screening; directly comparable in virology focus and Chinese government backing.
• The Pirbright Institute: UK government-funded institute specializing in viral diseases of livestock and viruses that jump to humans; comparable as a specialized virology reference center with high-containment facilities and national reference laboratory status.
• Shanghai Institute of Materia Medica, Chinese Academy of Sciences: CAS-affiliated institute focused on drug discovery that WIV partners with on antiviral research; comparable as a sister CAS research institution with similar funding model and collaborative drug screening programs.
• Chinese Academy of Medical Sciences, Institute of Pathogenic Biology: China's national medical research institute specializing in pathogen biology that WIV partners with on research exchange; comparable as a peer Chinese virology and infectious disease research organization with national strategic mandate.
• Institut Pasteur of Shanghai: Sino-French virology research institute with WHO reference laboratory status focused on emerging infectious diseases; directly comparable to WIV in mission, Chinese location, and international research collaboration profile.

Broad incumbents

• Chinese Center for Disease Control and Prevention (China CDC): China's national public health agency that receives pathogen samples and coordinates outbreak response; closely collaborates with WIV as the upstream research and reference laboratory counterpart in China's epidemic response ecosystem.
• Korea Disease Control and Prevention Agency (KDCA): South Korea's national public health agency with pathogen surveillance and reference laboratory capabilities; comparable as a government-backed infectious disease research and response institution in the Asia-Pacific region.
• NIH National Institute of Allergy and Infectious Diseases (NIAID) Rocky Mountain Laboratories: US government-operated high-containment virology laboratory with BSL-4 capacity focused on emerging infectious diseases; comparable as a national strategic asset with pathogen identification and pandemic response roles analogous to WIV.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Wuhan Institute of Virology